AU2021281256A1 - PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders - Google Patents
PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders Download PDFInfo
- Publication number
- AU2021281256A1 AU2021281256A1 AU2021281256A AU2021281256A AU2021281256A1 AU 2021281256 A1 AU2021281256 A1 AU 2021281256A1 AU 2021281256 A AU2021281256 A AU 2021281256A AU 2021281256 A AU2021281256 A AU 2021281256A AU 2021281256 A1 AU2021281256 A1 AU 2021281256A1
- Authority
- AU
- Australia
- Prior art keywords
- ldl
- subject
- pcsk9
- inhibitor
- hefh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032451P | 2020-05-29 | 2020-05-29 | |
| US63/032,451 | 2020-05-29 | ||
| PCT/US2021/034489 WO2021243002A1 (en) | 2020-05-29 | 2021-05-27 | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021281256A1 true AU2021281256A1 (en) | 2022-12-22 |
Family
ID=78722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021281256A Pending AU2021281256A1 (en) | 2020-05-29 | 2021-05-27 | PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235085A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4157887A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527542A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916838A (cg-RX-API-DMAC7.html) |
| AR (1) | AR122180A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021281256A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179316A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298375A (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20220322A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202210524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021243002A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| WO2025036347A1 (zh) | 2023-08-14 | 2025-02-20 | 信立泰(成都)生物技术有限公司 | Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法 |
| WO2025265012A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Compositions comprising anti-pcsk9 antbodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| KR20230074283A (ko) * | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
-
2021
- 2021-05-27 WO PCT/US2021/034489 patent/WO2021243002A1/en not_active Ceased
- 2021-05-27 US US17/999,373 patent/US20230235085A1/en active Pending
- 2021-05-27 AU AU2021281256A patent/AU2021281256A1/en active Pending
- 2021-05-27 CA CA3179316A patent/CA3179316A1/en active Pending
- 2021-05-27 CN CN202180039317.4A patent/CN115916838A/zh active Pending
- 2021-05-27 IL IL298375A patent/IL298375A/en unknown
- 2021-05-27 JP JP2022573247A patent/JP2023527542A/ja active Pending
- 2021-05-27 AR ARP210101427A patent/AR122180A1/es unknown
- 2021-05-27 EP EP21812361.0A patent/EP4157887A4/en active Pending
- 2021-05-28 TW TW110119435A patent/TW202210524A/zh unknown
-
2022
- 2022-11-27 JO JOJO/P/2022/0322A patent/JOP20220322A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527542A (ja) | 2023-06-29 |
| US20230235085A1 (en) | 2023-07-27 |
| CN115916838A (zh) | 2023-04-04 |
| EP4157887A4 (en) | 2024-07-03 |
| JOP20220322A1 (ar) | 2022-11-27 |
| TW202210524A (zh) | 2022-03-16 |
| CA3179316A1 (en) | 2021-12-02 |
| EP4157887A1 (en) | 2023-04-05 |
| AR122180A1 (es) | 2022-08-24 |
| IL298375A (en) | 2023-01-01 |
| WO2021243002A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331122B2 (en) | Anti-ASGR-1 monoclonal inhibitory antibodies | |
| US20230235085A1 (en) | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders | |
| EP2074149B1 (en) | Compositions and methods relating to glucagon receptor antibodies | |
| JP4898976B2 (ja) | Pcsk9拮抗薬 | |
| US20230117883A1 (en) | Muscle-targeting complexes and uses thereof in treating muscle atrophy | |
| JP7783840B2 (ja) | 抗ctla-4結合タンパク質及びその使用方法 | |
| WO2021253002A1 (en) | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof | |
| JP2015514708A (ja) | 抗emp2療法による癌幹細胞の低減 | |
| US20120269814A1 (en) | Anti-c mpl antibodies | |
| WO2020142626A1 (en) | Anti-ox40 binding proteins and methods of use thereof | |
| HK40090853A (en) | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders | |
| US20250289903A1 (en) | Methods and compositions for treating eosinophil driven diseases and disorders | |
| TW202323300A (zh) | 抗tigit構築體及其用途 | |
| TW202611078A (zh) | 以雙特異性BCMAxCD3抗體治療多發性骨髓瘤之方法 |